Evaluation of a “Meds‐to‐Beds” program on 30‐day hospital readmissions

Abstract

Background: Effective programs for transitional care from hospital to home are needed to improve patient outcomes.Purpose: To evaluate readmissions among patients who received a medication discharge program compared with control patients who did not receive the program.Methods: This was a retrospective, observational cohort study during a 1-year period in a medium-sized Midwestern health system. The "meds-to-beds" program consisted of a pharmacist and/or technician delivering patient's medications to bedside prior to discharge. When indicated, the pharmacist provided medication counseling, reviewed discharge medications, and provided an updated medication list to patients.The intervention cohort was defined as all hospitalized patients eligible for and opting into the "meds-to-beds" program. The control cohort was defined as hospitalized patients eligible for the program who did not opt-in to receive it. Data were collected through both a retrospective chart review and an administrative claims data warehouse. The primary outcome was defined as any 30-day readmissions. Secondary outcomes were defined as any preventable 30-day readmissions using the Agency for Healthcare Research and Quality's potentially avoidable hospitalization for ambulatory care sensitive conditions classification. Multivariable logistic regression models examined the odds of 30-day readmissions between the intervention and control groups.Results: Data were collected for 500 intervention and 1591 control patients. Both groups were similar with respect to age, gender, race, co-morbid conditions, and previous health care utilization. In the multivariable model, all-cause readmissions within 30 days were not significantly different between the intervention and control groups (odds ratio [OR] = 0.67; 95% confidence interval [CI]: 0.42-1.07, P = .09). The most common preventable readmissions were for pneumonia (43.2%), heart failure (18.9%), and dehydration (16.2%). In the multivariable model, patients

Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States

“…To our knowledge, no prior budget impact analysis for fidaxomicin has accounted for patients receiving a portion of therapy in an inpatient setting and the remainder in an outpatient setting. Factoring into the analysis the portion of therapy received in an outpatient setting is important for providing a complete assessment of budget impact for hospitals that own or are affiliated with outpatient pharmacies, including those involved in the ''meds-tobeds programs'' [39,40].…”